RU2010151951A - Общие пролекарства гепатопротектора и ацетаминофена - Google Patents
Общие пролекарства гепатопротектора и ацетаминофена Download PDFInfo
- Publication number
- RU2010151951A RU2010151951A RU2010151951/15A RU2010151951A RU2010151951A RU 2010151951 A RU2010151951 A RU 2010151951A RU 2010151951/15 A RU2010151951/15 A RU 2010151951/15A RU 2010151951 A RU2010151951 A RU 2010151951A RU 2010151951 A RU2010151951 A RU 2010151951A
- Authority
- RU
- Russia
- Prior art keywords
- compound
- compound according
- substituted
- unsubstituted
- amino acid
- Prior art date
Links
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 title claims 24
- 238000000034 method Methods 0.000 title claims 18
- 229960005489 paracetamol Drugs 0.000 title claims 12
- 150000001875 compounds Chemical class 0.000 claims abstract 139
- 150000001413 amino acids Chemical group 0.000 claims abstract 28
- 150000003839 salts Chemical class 0.000 claims abstract 17
- 239000012453 solvate Substances 0.000 claims abstract 17
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims abstract 12
- 239000012634 fragment Substances 0.000 claims abstract 11
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract 9
- 239000004471 Glycine Substances 0.000 claims abstract 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract 5
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 claims abstract 4
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims abstract 3
- 125000003835 nucleoside group Chemical group 0.000 claims abstract 3
- URNSECGXFRDEDC-UHFFFAOYSA-N N-acetyl-1,4-benzoquinone imine Chemical compound CC(=O)N=C1C=CC(=O)C=C1 URNSECGXFRDEDC-UHFFFAOYSA-N 0.000 claims 9
- 230000006378 damage Effects 0.000 claims 8
- 206010061218 Inflammation Diseases 0.000 claims 7
- 208000002193 Pain Diseases 0.000 claims 7
- 206010037660 Pyrexia Diseases 0.000 claims 7
- 230000004054 inflammatory process Effects 0.000 claims 7
- 230000003961 neuronal insult Effects 0.000 claims 7
- 238000002360 preparation method Methods 0.000 claims 6
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims 5
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 5
- 235000018417 cysteine Nutrition 0.000 claims 5
- 230000000302 ischemic effect Effects 0.000 claims 5
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims 4
- 229930182817 methionine Natural products 0.000 claims 4
- 206010019851 Hepatotoxicity Diseases 0.000 claims 3
- -1 alkylene phosphate Chemical compound 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 229930195712 glutamate Natural products 0.000 claims 3
- 231100000304 hepatotoxicity Toxicity 0.000 claims 3
- 230000007686 hepatotoxicity Effects 0.000 claims 3
- 230000000415 inactivating effect Effects 0.000 claims 3
- 108010024636 Glutathione Proteins 0.000 claims 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 claims 2
- 150000001944 cysteine derivatives Chemical group 0.000 claims 2
- 229960004193 dextropropoxyphene Drugs 0.000 claims 2
- XLMALTXPSGQGBX-GCJKJVERSA-N dextropropoxyphene Chemical compound C([C@](OC(=O)CC)([C@H](C)CN(C)C)C=1C=CC=CC=1)C1=CC=CC=C1 XLMALTXPSGQGBX-GCJKJVERSA-N 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 229960003180 glutathione Drugs 0.000 claims 2
- 230000002443 hepatoprotective effect Effects 0.000 claims 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 claims 2
- 208000037906 ischaemic injury Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 claims 2
- 231100000816 toxic dose Toxicity 0.000 claims 2
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 claims 1
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 claims 1
- ATOTUUBRFJHZQG-UHFFFAOYSA-N 2-amino-2-methylpropan-1-ol;8-bromo-1,3-dimethyl-7h-purine-2,6-dione Chemical compound CC(C)(N)CO.O=C1N(C)C(=O)N(C)C2=C1NC(Br)=N2 ATOTUUBRFJHZQG-UHFFFAOYSA-N 0.000 claims 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims 1
- JAQUASYNZVUNQP-USXIJHARSA-N Levorphanol Chemical compound C1C2=CC=C(O)C=C2[C@]23CCN(C)[C@H]1[C@@H]2CCCC3 JAQUASYNZVUNQP-USXIJHARSA-N 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- ZRVUJXDFFKFLMG-UHFFFAOYSA-N Meloxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=NC=C(C)S1 ZRVUJXDFFKFLMG-UHFFFAOYSA-N 0.000 claims 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 229960004308 acetylcysteine Drugs 0.000 claims 1
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 1
- 235000001014 amino acid Nutrition 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims 1
- 229940049706 benzodiazepine Drugs 0.000 claims 1
- UZVHFVZFNXBMQJ-UHFFFAOYSA-N butalbital Chemical compound CC(C)CC1(CC=C)C(=O)NC(=O)NC1=O UZVHFVZFNXBMQJ-UHFFFAOYSA-N 0.000 claims 1
- 229960002546 butalbital Drugs 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- OFZCIYFFPZCNJE-UHFFFAOYSA-N carisoprodol Chemical compound NC(=O)OCC(C)(CCC)COC(=O)NC(C)C OFZCIYFFPZCNJE-UHFFFAOYSA-N 0.000 claims 1
- 229960004587 carisoprodol Drugs 0.000 claims 1
- 229960004126 codeine Drugs 0.000 claims 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 claims 1
- 229960003529 diazepam Drugs 0.000 claims 1
- 229960001259 diclofenac Drugs 0.000 claims 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 claims 1
- HCFDWZZGGLSKEP-UHFFFAOYSA-N doxylamine Chemical compound C=1C=CC=NC=1C(C)(OCCN(C)C)C1=CC=CC=C1 HCFDWZZGGLSKEP-UHFFFAOYSA-N 0.000 claims 1
- 229960005178 doxylamine Drugs 0.000 claims 1
- 229960005293 etodolac Drugs 0.000 claims 1
- XFBVBWWRPKNWHW-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=N[C]3C(CC)=CC=CC3=C21 XFBVBWWRPKNWHW-UHFFFAOYSA-N 0.000 claims 1
- 229960002390 flurbiprofen Drugs 0.000 claims 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims 1
- 150000002306 glutamic acid derivatives Chemical class 0.000 claims 1
- 150000002332 glycine derivatives Chemical class 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 claims 1
- 229960000240 hydrocodone Drugs 0.000 claims 1
- WVLOADHCBXTIJK-YNHQPCIGSA-N hydromorphone Chemical compound O([C@H]1C(CC[C@H]23)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O WVLOADHCBXTIJK-YNHQPCIGSA-N 0.000 claims 1
- 229960001410 hydromorphone Drugs 0.000 claims 1
- 229960001680 ibuprofen Drugs 0.000 claims 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 1
- 229960000991 ketoprofen Drugs 0.000 claims 1
- 229960004752 ketorolac Drugs 0.000 claims 1
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims 1
- 229960003406 levorphanol Drugs 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 229960004391 lorazepam Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960001929 meloxicam Drugs 0.000 claims 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 claims 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims 1
- 229960003793 midazolam Drugs 0.000 claims 1
- 229960005249 misoprostol Drugs 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- VTCDEJZIEHTNBC-UHFFFAOYSA-N n-(2,5-dioxocyclohex-3-en-1-ylidene)acetamide Chemical class CC(=O)N=C1CC(=O)C=CC1=O VTCDEJZIEHTNBC-UHFFFAOYSA-N 0.000 claims 1
- 229960002009 naproxen Drugs 0.000 claims 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
- 229960003357 pamabrom Drugs 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 229960002702 piroxicam Drugs 0.000 claims 1
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229960004380 tramadol Drugs 0.000 claims 1
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
- C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5477708P | 2008-05-20 | 2008-05-20 | |
| US61/054,777 | 2008-05-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2010151951A true RU2010151951A (ru) | 2012-06-27 |
Family
ID=41340540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010151951/15A RU2010151951A (ru) | 2008-05-20 | 2009-05-20 | Общие пролекарства гепатопротектора и ацетаминофена |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20110263545A1 (enExample) |
| EP (1) | EP2285419A4 (enExample) |
| JP (6) | JP5701750B2 (enExample) |
| KR (1) | KR101717145B1 (enExample) |
| CN (1) | CN102149412A (enExample) |
| AU (1) | AU2009249071A1 (enExample) |
| BR (1) | BRPI0912820A2 (enExample) |
| CA (2) | CA2946445C (enExample) |
| IL (1) | IL209384A0 (enExample) |
| MX (1) | MX2010012647A (enExample) |
| RU (1) | RU2010151951A (enExample) |
| WO (1) | WO2009143299A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5757864B2 (ja) * | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| AU2009249071A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
| AU2009249069A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Carbonate prodrugs and methods of using the same |
| EP2758133A4 (en) | 2011-09-22 | 2015-05-27 | Acorda Therapeutics Inc | ACETAMINOPHONE CONJUGATES, COMPOSITIONS AND METHOD OF USE THEREOF |
| US20140179615A1 (en) * | 2012-07-12 | 2014-06-26 | Hainan Weikang Pharmaceutical (Qianshan) Co., Ltd. | Glutathione and Acetaminophen Composition and Preparation Method Thereof |
| CA3042642A1 (en) | 2013-08-12 | 2015-02-19 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
| WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
| DK3169315T3 (da) | 2014-07-17 | 2020-08-10 | Pharmaceutical Manufacturing Res Services In | Væskefyldt doseringsform til forhindring af misbrug med øjeblikkelig frigivelse |
| WO2016025897A1 (en) * | 2014-08-15 | 2016-02-18 | Purdue Pharma L.P. | Acetaminophen-containing analgesic formulations with reduced hepatotoxicity |
| AU2015336065A1 (en) | 2014-10-20 | 2017-05-04 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
| US11389409B2 (en) * | 2019-08-30 | 2022-07-19 | Remedy Diagnostics LLC | Transdermal device comprising acetaminophen prodrug |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4035507A (en) * | 1975-04-17 | 1977-07-12 | Interx Research Corporation | Novel, transient pro-drug forms of L-DOPA to treat Parkinson's disease |
| GB1583602A (en) | 1977-05-26 | 1981-01-28 | Sterwin Ag | N-acetyl-para-aminophenyl-n'-acetyl-amino-thioalkanoic acid ester derivatives |
| US4562024A (en) | 1982-07-06 | 1985-12-31 | Sterling Drug Inc. | Process for preparing granulate containing poorly compressible medicinally active matter |
| CH654302A5 (de) * | 1983-05-04 | 1986-02-14 | Sandoz Ag | Acylaminophenolderivate, ihre herstellung und arzneimittel, welche sie enthalten. |
| US5001115A (en) * | 1989-05-17 | 1991-03-19 | University Of Florida | Prodrugs of biologically active hydroxyaromatic compounds |
| US5474757A (en) * | 1992-10-16 | 1995-12-12 | Rutgers University | Prevention of acetaminophen overdose toxicity with organosulfur compounds |
| DE4327462A1 (de) * | 1993-08-16 | 1995-02-23 | Carl Heinrich Dr Weischer | Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen |
| US5916910A (en) | 1997-06-04 | 1999-06-29 | Medinox, Inc. | Conjugates of dithiocarbamates with pharmacologically active agents and uses therefore |
| US6710086B1 (en) | 2000-02-25 | 2004-03-23 | Medinox, Inc. | Protected forms of pharmacologically active agents and uses therefor |
| ES2234840T3 (es) | 2000-03-14 | 2005-07-01 | Actelion Pharmaceuticals Ltd. | Derivados de 1,2,3,4- tetrahidroisoquinolina. |
| WO2001068069A2 (en) | 2000-03-15 | 2001-09-20 | King's College London | Pharmaceutical composition comprising paracetamol |
| IT1319202B1 (it) | 2000-10-12 | 2003-09-26 | Nicox Sa | Farmaci per le malattie a base infiammatoria. |
| US20030073618A1 (en) * | 2001-02-08 | 2003-04-17 | Kozhemyakin Leonid A. | Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof |
| KR20030033007A (ko) | 2001-05-31 | 2003-04-26 | 코울터 파머수티컬, 인코포레이티드 | 세포독소, 약물전구체, 링커 및 이에 유용한 안정화제 |
| NZ529661A (en) | 2001-06-05 | 2006-03-31 | Control Delivery Systems | Sustained-release analgesic compounds |
| US20030118528A1 (en) | 2001-11-19 | 2003-06-26 | Walters Kenneth A. | Topical delivery of codrugs |
| US20050164994A1 (en) | 2001-12-10 | 2005-07-28 | Control Deliver Systems, Inc. | Treatment of genitourinary tract disorders |
| EP1461122A4 (en) | 2001-12-10 | 2006-08-23 | Control Delivery Sys Inc | TREATMENT OF DISEASES OF THE UROGENITAL SYSTEM |
| WO2003061626A1 (en) | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| US20040058946A1 (en) | 2002-07-05 | 2004-03-25 | Buchwald Stephen L. | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals |
| US7381721B2 (en) | 2003-03-17 | 2008-06-03 | Adolor Corporation | Substituted piperidine compounds |
| KR20140015122A (ko) | 2003-10-01 | 2014-02-06 | 아돌로 코포레이션 | 스피로시클릭 헤테로시클릭 유도체 및 이의 사용 방법 |
| CN100453528C (zh) | 2003-11-12 | 2009-01-21 | 应用超微系统股份有限公司 | 非对称胶凝剂 |
| US20050113294A1 (en) | 2003-11-21 | 2005-05-26 | Adolor Corporation. | Carboxamide and amino derivatives and methods of their use |
| TW200616604A (en) | 2004-08-26 | 2006-06-01 | Nicholas Piramal India Ltd | Nitric oxide releasing prodrugs containing bio-cleavable linker |
| US7598261B2 (en) | 2005-03-31 | 2009-10-06 | Adolor Corporation | Spirocyclic heterocyclic derivatives and methods of their use |
| JP2009502931A (ja) | 2005-07-27 | 2009-01-29 | オレキシジェン・セラピューティクス・インコーポレーテッド | 体重減少を促すための組成物 |
| EP1998781A2 (en) | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Treatment of pain |
| EP2121029A2 (en) | 2006-12-05 | 2009-11-25 | Neurogesx, Inc. | Prodrugs and methods of making and using the same |
| JP5757864B2 (ja) | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| AU2009249071A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Hepatoprotectant acetaminophen mutual prodrugs |
| AU2009249069A1 (en) | 2008-05-20 | 2009-11-26 | Neurogesx, Inc. | Carbonate prodrugs and methods of using the same |
-
2009
- 2009-05-20 AU AU2009249071A patent/AU2009249071A1/en not_active Abandoned
- 2009-05-20 JP JP2011510694A patent/JP5701750B2/ja not_active Expired - Fee Related
- 2009-05-20 RU RU2010151951/15A patent/RU2010151951A/ru not_active Application Discontinuation
- 2009-05-20 WO PCT/US2009/044749 patent/WO2009143299A1/en not_active Ceased
- 2009-05-20 KR KR1020107028511A patent/KR101717145B1/ko not_active Expired - Fee Related
- 2009-05-20 CA CA2946445A patent/CA2946445C/en not_active Expired - Fee Related
- 2009-05-20 CA CA2724788A patent/CA2724788C/en not_active Expired - Fee Related
- 2009-05-20 US US12/993,091 patent/US20110263545A1/en not_active Abandoned
- 2009-05-20 CN CN2009801282430A patent/CN102149412A/zh active Pending
- 2009-05-20 EP EP09751527A patent/EP2285419A4/en not_active Withdrawn
- 2009-05-20 BR BRPI0912820A patent/BRPI0912820A2/pt not_active IP Right Cessation
- 2009-05-20 MX MX2010012647A patent/MX2010012647A/es active IP Right Grant
-
2010
- 2010-11-17 IL IL209384A patent/IL209384A0/en unknown
-
2014
- 2014-02-03 JP JP2014018474A patent/JP2014111632A/ja not_active Withdrawn
-
2015
- 2015-09-14 JP JP2015180278A patent/JP2015227384A/ja not_active Withdrawn
-
2016
- 2016-05-09 US US15/150,099 patent/US9951001B2/en not_active Expired - Fee Related
-
2017
- 2017-07-20 JP JP2017140812A patent/JP2017186380A/ja not_active Withdrawn
-
2018
- 2018-03-15 US US15/922,273 patent/US20190062273A1/en not_active Abandoned
-
2019
- 2019-02-27 JP JP2019034258A patent/JP2019081793A/ja not_active Withdrawn
-
2020
- 2020-12-04 JP JP2020201931A patent/JP2021036001A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010012647A (es) | 2010-12-14 |
| EP2285419A1 (en) | 2011-02-23 |
| CA2724788A1 (en) | 2009-11-26 |
| JP2019081793A (ja) | 2019-05-30 |
| US20190062273A1 (en) | 2019-02-28 |
| JP2011523645A (ja) | 2011-08-18 |
| CA2724788C (en) | 2016-12-06 |
| JP2014111632A (ja) | 2014-06-19 |
| JP2017186380A (ja) | 2017-10-12 |
| JP2015227384A (ja) | 2015-12-17 |
| US20110263545A1 (en) | 2011-10-27 |
| US9951001B2 (en) | 2018-04-24 |
| WO2009143299A1 (en) | 2009-11-26 |
| AU2009249071A1 (en) | 2009-11-26 |
| BRPI0912820A2 (pt) | 2015-10-13 |
| KR101717145B1 (ko) | 2017-03-16 |
| US20160326107A1 (en) | 2016-11-10 |
| KR20110011694A (ko) | 2011-02-08 |
| JP2021036001A (ja) | 2021-03-04 |
| EP2285419A4 (en) | 2012-05-02 |
| IL209384A0 (en) | 2011-01-31 |
| CA2946445C (en) | 2019-01-08 |
| CA2946445A1 (en) | 2009-11-26 |
| CN102149412A (zh) | 2011-08-10 |
| JP5701750B2 (ja) | 2015-04-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011523645A5 (enExample) | ||
| RU2010151952A (ru) | Водорастворимые аналоги ацетаминофена | |
| KR101717145B1 (ko) | 간보호제 아세트아미노펜 공통 프로드러그 | |
| TWI440641B (zh) | 蛋白酶體抑制劑 | |
| JP2011520977A5 (enExample) | ||
| ES2661583T3 (es) | Métodos y composiciones usando inhibidores de PDE4 para el tratamiento y gestión de enfermedades autoinmunes e inflamatorias | |
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| RU2003117459A (ru) | Нафталиновые производные | |
| ES2325163T3 (es) | Compuestos analgesicos, su sintesis y composiciones farmaceuticas que los contienen. | |
| ES3058652T3 (en) | Formulations for administration of eflornithine | |
| RU2014141362A (ru) | Комбинированная терапия пролиферативных нарушений | |
| RU2013144368A (ru) | Пролекарства действующих веществ гетероциклическими линкерами | |
| RU2009101324A (ru) | Композиции и способы лечения воспаления слизистой оболочки | |
| EP2051735A2 (en) | Conjugates comprising a gaba- or glycine compound, pharmaceutical compositions and combinations thereof as well as their use in treating cns disorders | |
| JP2017505314A (ja) | Ｈｂｖ感染の治療のための併用療法 | |
| ES2698363T3 (es) | Composiciones de oxprenolol para tratar el cáncer | |
| ES2505325T3 (es) | Bencenopropanamida N-sustituida o derivados de bencenopropenamida para su uso en el tratamiento del dolor | |
| ES2373838T3 (es) | Medicamento así como su preparación y su utilización en el tratamiento de neuropatías dolorosas. | |
| JP7116792B2 (ja) | 疼痛を緩和するための組成物および方法 | |
| CN107540726A (zh) | 一类肽基塞来昔布衍生物及其应用 | |
| ES2535452B1 (es) | Potenciación del efecto del metotrexato mediante el uso combinado con estatinas lipofílicas | |
| ES2280196T3 (es) | Utilizacion de r-acidos arilpropionicos para la preparacion de medicamentos destinados al tratamiento de enfermedades en seres humanos y animales, sobre las que se puede influir terapeuticamente mediante la inhibicion de la activacion de nf-kb. | |
| ES2983998T3 (es) | Compuesto de indol para tratar la cistitis intersticial | |
| ES2770362T3 (es) | Bencenopropanamida N-sustituida para su uso en el tratamiento del dolor y la inflamación | |
| CN101232880A (zh) | Hdac抑制剂在治疗骨髓瘤中的用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20131024 |